Table 2.
The 10 most frequently claimed medicines in 2015
| Medicine | Number of claims (% of total) | • Indications | Number of successful claims | Number of unsuccessful claims |
|---|---|---|---|---|
| Abiraterone acetate | 4 (10%) | • Prostate cancer | 4 | 0 |
| Cetuximab | 8 (20%) | • Colon/colorectal cancer** | 4 | 1 |
| • Unspecified | 2 | 0 | ||
| • Endometrial cancer | 1 | 0 | ||
| Lenalidomide | 3 (7%) | • Multiple myeloma | 3 | 0 |
| Regorafenib | 4 (10%) | • Colon/colorectal cancer** | 3 | 1 |
| Pirfenidone | 3 (7%) | • Pulmonary fibrosis | 2 | 1 |
| Sorafenib | 3 (7%) | • Hepatocellular cancer | 2 | 0 |
| • Renal cancer | 0 | 1 | ||
| Paclitaxel | 2 (5%) | • Pancreatic cancer** | 2 | 0 |
| Rituximab | 2 (5%) | • Nephrotic syndrome | 1 | 0 |
| • Lupus | 0 | 1 | ||
| TDM-1 (trastuzumab-emitansine) | 3 (7%) | • Unspecified | 2 | 0 |
| • Metastatic breast cancer | 0 | 1 | ||
| Ibrutinib | 2 (5%) | • Chronic lymphoid leukemia | 1 | 0 |
| • Unspecified | 1 | 0 |
**
Includes both metastatic (advanced) stages of the same pathology. and non-metastatic disease because the court decisions did not systematically differentiate between the two